Vicadrostat - Boehringer Ingelheim
Alternative Names: BI-690517; C 14Latest Information Update: 05 Dec 2024
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Class 2 ring heterocyclic compounds; Alcohols; Benzonitrile; Chlorinated hydrocarbons; Imidazoles; Pyrones; Small molecules; Urologics
- Mechanism of Action Aldosterone synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Heart failure; Renal failure
- No development reported Diabetic nephropathies
Most Recent Events
- 05 Dec 2024 Chemical structure information added.
- 04 Dec 2024 Boehringer Ingelheim initiates a phase I pharmacokinetics trial (In volunteers) (PO) (NCT06647810)
- 18 Oct 2024 Boehringer Ingelheim plans a phase I pharmacokinetics trial (In volunteers) (PO), in November 2024 (NCT06647810)